Emily J Clarke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily J Clarke has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Catriona S. Bradshaw
Melbourne Sexual Health Centre, Alfred Health
2 shared publications Christopher K Fairley
Melbourne Sexual Health Centre, Alfred Health , Carlton, Victoria , Australia
2 shared publicationsEric P F Chow
Melbourne Sexual Health Centre, Alfred Health , Carlton, Victoria , Australia
2 shared publications- Erica Louise Plummer
School of Translational Medicine, Monash University, Melbourne, Victoria, Australia
2 shared publications Ivette Aguirre
Melbourne Sexual Health Centre, Alfred Health , Carlton, Victoria , Australia
2 shared publications- Lenka A. Vodstrcil
Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia
2 shared publications
Latest Publications
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (12) , ofad590
Efficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance
Antimicrobial resistance in Mycoplasma genitalium is rising globally and antimicrobial options are limited. We evaluated the efficacy of sitafloxacin regimens for macrolide-resistant M genitalium at Melbourne Sexual Health Centre, Australia, between January 2017 and February 2022. Before June 2017, patients received doxycycline followed by sitafloxacin; subsequently, patients received doxycycline followed by combined doxycycline + sitafloxacin. Of 229 patients treated with a sitafloxacin regimen, 80.6% experienced microbial cure. Sitafloxacin cured 94.2% of infections that had not previously failed moxifloxacin and 69.5% of infections that had; prior failure of moxifloxacin was associated with an 8-fold odds of sitafloxacin failure. There was no difference in cure between sequential monotherapy and combination therapy when patients were stratified by past failure of moxifloxacin (P > .05); however, small numbers limited comparisons. Sitafloxacin was well tolerated and still achieved 70% cure in patients in whom moxifloxacin had failed. These data highlight the benefit of incorporating relevant fluoroquinolone resistance markers into assays to assist clinical decision making.
- 22 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (12) , ofad590
Open AccessEfficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance
Antimicrobial resistance in Mycoplasma genitalium is rising globally and antimicrobial options are limited. We evaluated the efficacy of sitafloxacin regimens for macrolide-resistant M genitalium at Melbourne Sexual Health Centre, Australia, between January 2017 and February 2022. Before June 2017, patients received doxycycline followed by sitafloxacin; subsequently, patients received doxycycline followed by combined doxycycline + sitafloxacin. Of 229 patients treated with a sitafloxacin regimen, 80.6% experienced microbial cure. Sitafloxacin cured 94.2% of infections that had not previously failed moxifloxacin and 69.5% of infections that had; prior failure of moxifloxacin was associated with an 8-fold odds of sitafloxacin failure. There was no difference in cure between sequential monotherapy and combination therapy when patients were stratified by past failure of moxifloxacin (P > .05); however, small numbers limited comparisons. Sitafloxacin was well tolerated and still achieved 70% cure in patients in whom moxifloxacin had failed. These data highlight the benefit of incorporating relevant fluoroquinolone resistance markers into assays to assist clinical decision making.
- Open Access
- 1 August 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad427
Efficacy of Minocycline for the Treatment ofMycoplasma genitalium
High levels of macrolide resistance and increasing fluoroquinolone resistance are making Mycoplasma genitalium increasingly difficult to treat. Minocycline is an alternative treatment for patients with macrolide-resistant M. genitalium infections that have failed moxifloxacin, or for those with fluoroquinolone contraindications or resistance. Published efficacy data for minocycline for M. genitalium are limited. We evaluated minocycline 100 mg BD for 14 days at Melbourne Sexual Health Centre (MSHC). Microbial cure was defined as a negative test-of-cure within 14-90 days after completing minocycline. The proportion cured with 95% confidence intervals (CI) was calculated and logistic regression was used to explore factors associated with treatment failure. We pooled data from the current study with a prior adjacent case series of patients with M. genitalium who had received minocycline 100 mg BD for 14 days at MSHC. Minocycline cured 60 of 90 (67%, 95% confidence interval (CI) 56-76%) infections. Adherence was high (96%) and side-effects were mild and self-limiting. No demographic or clinical characteristics were associated with minocycline failure in regression analyses. In the pooled analyses of 123 patients, 83 (68%, 95% CI 58-76) were cured following minocycline. Minocycline cured 68% of macrolide-resistant M. genitalium infections. These data provide tighter precision around the efficacy of minocycline for macrolide-resistant M. genitalium and show that it is a well- tolerated regimen. With high levels of macrolide-resistance, increasing fluoroquinolone resistance, and the high cost of moxifloxacin, access to non-quinolone options such as minocycline is increasingly important for the clinical management of M. genitalium.
- 1 August 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (8) , ofad427
Open AccessEfficacy of Minocycline for the Treatment ofMycoplasma genitalium
High levels of macrolide resistance and increasing fluoroquinolone resistance are making Mycoplasma genitalium increasingly difficult to treat. Minocycline is an alternative treatment for patients with macrolide-resistant M. genitalium infections that have failed moxifloxacin, or for those with fluoroquinolone contraindications or resistance. Published efficacy data for minocycline for M. genitalium are limited. We evaluated minocycline 100 mg BD for 14 days at Melbourne Sexual Health Centre (MSHC). Microbial cure was defined as a negative test-of-cure within 14-90 days after completing minocycline. The proportion cured with 95% confidence intervals (CI) was calculated and logistic regression was used to explore factors associated with treatment failure. We pooled data from the current study with a prior adjacent case series of patients with M. genitalium who had received minocycline 100 mg BD for 14 days at MSHC. Minocycline cured 60 of 90 (67%, 95% confidence interval (CI) 56-76%) infections. Adherence was high (96%) and side-effects were mild and self-limiting. No demographic or clinical characteristics were associated with minocycline failure in regression analyses. In the pooled analyses of 123 patients, 83 (68%, 95% CI 58-76) were cured following minocycline. Minocycline cured 68% of macrolide-resistant M. genitalium infections. These data provide tighter precision around the efficacy of minocycline for macrolide-resistant M. genitalium and show that it is a well- tolerated regimen. With high levels of macrolide-resistance, increasing fluoroquinolone resistance, and the high cost of moxifloxacin, access to non-quinolone options such as minocycline is increasingly important for the clinical management of M. genitalium.